Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes

Journal of Virological Methods

Volumn 194, Issue 1-2, 2013, Pages 52-59

  Zhang, Wen feng ^a,b   Wu, Feng lin ^a,b   Shao, Hong wei ^a   Wang, Teng ^a,b   Huang, Xiao tong ^a   Li, Wen li ^a   Shen, Han ^a,b   Huang, Shu lin ^a,b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chimeric adenoviral vector; T cell receptor; Transduction efficiency

Indexed keywords

ADENOVIRUS VECTOR; CELL SURFACE RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN;

CHIMERIC ADENOVIRAL VECTOR; T CELL RECEPTOR; TRANSDUCTION EFFICIENCY;

ADENOVIRUSES, HUMAN; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84883418374     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.07.052     Document Type: Article

References (36)

1. Addison C.L., Hitt M., Kunsken D., Graham F.L. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. Journal of General Virology 1997, 78:1653-1661.
2. Balasubramanian K., Schroit A.J. Aminophospholipid asymmetry: a matter of life and death. Annual Review of Physiology 2003, 65:701-734.
3. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987, 329:506-512.
4. Brand K., Klocke R., Possling A., Paul D., Strauss M. Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Therapy 1999, 6:1054-1063.
5. Callahan M.K., Popernack P.M., Tsutsui S., Truong L., Schlegel R.A., Henderson A.J. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. Journal of Immunology 2003, 170:4840-4845.
6. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. Journal of Immunology 1999, 163:507-513.
7. Di Nicola M., Milanesi M., Magni M., Bregni M., Carlo S.C., Longoni P., Tomanin R., Ravagnani F., Scarpa M., Jordan C., Gianni A.M. Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. Human Gene Therapy 1999, 10:1875-1884.
8. Dunbar P.R., Chen J.L., Chao D., Rust N., Teisserenc H., Ogg G.S., Romero P., Weynants P., Cerundolo V. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. Journal of Immunology 1999, 162:6959-6962.
9. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nature Reviews Immunology 2006, 6:836-848.
10. Engels B., Uckert W. Redirecting T lymphocyte specificity by T cell receptor gene transfer-a new era for immunotherapy. Molecular Aspects of Medicine 2007, 28:115-142.
11. Fischer A. Cautious advance. Gene therapy is more complex than anticipated. EMBO Reports 2000, 1:294-296.
12. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
13. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M., Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine 2003, 348:255-256.
14. Huang S., Endo R.I., Nemerow G.R. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. Journal of Virology 1995, 69:2257-2263.
15. Huang R.T., Lichtenberg B., Rick O. Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection. FEBS Letters 1996, 392:59-62.
16. Ioannides C.G., Freedman R.S., Platsoucas C.D., Rashed S., Kim Y.P. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. Journal of Immunology 1991, 146:1700-1707.
17. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
18. Kay M.A., Glorioso J.C., Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Medicine 2001, 7:33-40.
19. Mercer J., Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 2008, 320:531-535.
20. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
21. Nicklin S.A., Wu E., Nemerow G.R., Baker A.H. The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy 2005, 12:384-393.
22. Samson M., Jung D. Intracellular trafficking and fate of chimeric adenovirus 5/F35 in human B lymphocytes. Journal of Gene Medicine 2011, 13:451-461.
23. Schaft N., Willemsen R.A., deVries J., Lankiewicz B., Essers B.W., Gratama J.W., Figdor C.G., Bolhuis R.L., Debets R., Adema G.J. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. Journal of Immunology 2003, 170:2186-2194.
24. Scholten K.B., Kramer D., Kueter E.W., Graf M., Schoedl T., Meijer C.J., Schreurs M.W., Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clinical Immunology 2006, 119:135-145.
25. Schroers R., Hildebrandt Y., Hasenkamp J., Glass B., Lieber A., Wulf G., Piesche M. Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Experimental Hematology 2004, 32:536-546.
26. Seigneuret M., Devaux P.F. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:3751-3755.
27. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. Journal of Virology 2000, 74:2567-2583.
28. Shayakhmetov D.M., Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. Journal of Virology 2000, 74:10274-10286.
29. Shen H., Shao H.W., Chen X.H., Wu F.L., Wang H., Huang Z.L., Shen J., Wang T., Zhang W.F., Huang S.L. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen. Cancer Immunology, Immunotherapy 2013, 62:393-403.
30. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature Medicine 2008, 14:1357-1362.
31. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3352-3356.
32. + T lymphocytes by MuLV-10A1 retrovirus pseudotype. Human Gene Therapy 2000, 11:1005-1014.
33. Uckert W., Schumacher T.N.M. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunology, Immunotherapy 2009, 58:809-822.
34. Williamson P., Schlegel R.A. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Molecular Membrane Biology 1994, 11:199-216.
35. Yang S., Cohen C.J., Peng P.D., Zhao Y., Cassard L., Yu Z., Zheng Z., Jones S., Restifo N.P., Rosenberg S.A., Morgan R.A. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Therapy 2008, 15:1411-1423.
36. Yotnda P., Savoldo B., Charlet-Berguerand N., Rooney C., Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 2004, 104:2272-2280.